Home・Список акций・Collegium Pharmaceutical Inc

C
Collegium Pharmaceutical Inc

Закрыт

СекторЗдравоохранение

35.58 0.71

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

34.65

Макс.

35.79

Ключевые показатели
By Trading Economics
Доход	-2.5M 14M
Продажи	-12M 194M
P/E Средняя по отрасли	17.077 64.641
Прибыль на акцию	1.76
Рентабельность продаж	7.491
Сотрудники	423
EBITDA	-213M 91M

Рекомендации
By TipRanks
Рекомендации	Активная покупка
Прогноз на 12 месяцев	+61.13% upside

Дивиденды
By Acuity
Следующий отчет о доходах	6 авг. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	31M 1.2B
Предыдущая цена открытия	34.87
Предыдущая цена закрытия	35.58

Новостные настроения

By Acuity

34%

66%

104 / 340 Рейтинг в Healthcare

Collegium Pharmaceutical Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

3 авг. 2026 г., 19:46 UTC

Collegium Pharmaceutical Inc is trading lower today, continuing a three-session decline. The stock peaked early but has since pulled back.

31 июл. 2026 г., 20:06 UTC

News

Collegium Pharmaceutical is under scrutiny due to concerns over its financial performance, contributing to a decline in shares during Friday's session.

30 июл. 2026 г., 20:09 UTC

Collegium Pharmaceutical Inc shares are lower in Thursday's session, with no specific news to explain the decline amid broader market volatility.

29 июл. 2026 г., 22:01 UTC

Collegium Pharmaceutical Inc is trading higher in after-market hours, continuing a positive trend with gains over four consecutive sessions amid cautious investor sentiment.

28 июл. 2026 г., 22:01 UTC

Collegium Pharmaceutical Inc shares are lower in after-market hours, continuing a decline from Tuesday's close amid broader market pressures, particularly in Asia.

27 июл. 2026 г., 19:07 UTC

News

Collegium Pharmaceutical reported first-quarter revenues of $193.5 million, surpassing expectations, while shares are trading higher amid broader strength in the pharmaceutical sector.

24 июл. 2026 г., 19:46 UTC

Collegium Pharmaceutical Inc shares are lower during Friday's session, with no specific news identified to explain the decline. The stock remains near its one-month trading range.

22 июл. 2026 г., 20:01 UTC

Collegium Pharmaceutical Inc shares are lower today, continuing a downward trend seen since Tuesday's close, with no specific news identified for the decline.

21 июл. 2026 г., 20:01 UTC

Collegium Pharmaceutical Inc is trading higher amid a broader market rally, with the Pharmaceuticals sector also gaining momentum. No specific news was identified.

20 июл. 2026 г., 19:41 UTC

News

Collegium Pharmaceutical plans to move its headquarters to Boston in 2027. Shares are lower amid significant declines in the Pharmaceuticals sub-sector.

Сравнение c конкурентами

Изменение цены

Collegium Pharmaceutical Inc Прогноз

Целевая цена

By TipRanks

61.13% рост

Прогноз на 12 месяцев

Средняя 57.33 USD 61.13%

Максимум 60 USD

Минимум 56 USD

Основано на мнении 4 аналитиков Wall Street, спрогнозировавших целевые цены для Collegium Pharmaceutical Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

4 ratings

Покупка

Удержание

Продажа

Основано на мнении 4 аналитиков, присваивавших рейтинги акциям Collegium Pharmaceutical Inc – Данные за последние 3 месяца.

Настроения

By Acuity

104 / 340Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Collegium Pharmaceutical Inc

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.